Tamoxifen in Duchenne Muscular Dystrophy

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

July 25, 2022

Study Completion Date

October 18, 2022

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Tamoxifen

DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.

DRUG

Matching placebo

Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.

Trial Locations (11)

4031

University Children's Hospital Basel, Basel

6525

Radboud umc, Nijmegen

14050

DRK Klinik Berlin Westend, Berlin

41013

Hospital Universitario Virgen del Rocío, Seville

45147

Universitätsklinikum Essen, Essen

67098

Hôpital de Hautepierre, Strasbourg

92380

Hôpitaux Raymond Poincaré, Garches

08950

Hospital Sant Joan de Déu. UB, Esplugues de Llobregat

G51 4TF

Royal Hospital for Children, Glasgow

LS9 7TF

The Leeds Teaching Hospitals NHS Trust, Leeds

L12 2AP

Alder Hey Children's Hospital, Liverpool

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT03354039 - Tamoxifen in Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter